The Stem Cell Blog – Page 647

Designed enzyme rescues live bacteria | January 22, 2018 Issue … – The Biological SCENE

2018-01-18 Michael Zand NEWS

Stem Cell Transplant Results Better than Standard Therapy in Severe Scleroderma Patients, Phase 2 Trial Shows – Scleroderma News

Scleroderma NewsStem Cell Transplant Results Better than Standard Therapy in Severe Scleroderma Patients, Phase 2 Trial ShowsScleroderma NewsResults from a Phase 2 clinical trial shows that stem cell transplants can provide better long-term benefits th… Continue reading

2018-01-18 Michael Zand NEWS

Global Synthetic Biology Workstation Market 2018-2022 – Increasing … – Business Wire (press release)

Ask Reporter 24Global Synthetic Biology Workstation Market 2018-2022 – Increasing …Business Wire (press release)One trend in the market is growing number of startups in synthetic biology. With the increasing number of venture capitalists willing to f… Continue reading

2018-01-18 Michael Zand NEWS

Gilead/Kite team up with Pfizer for CAR-T-mAb combination – FierceBiotech

Designed enzyme rescues live bacteria | January 22, 2018 Issue …
The Biological SCENE
Syn-F4 catalyzes the conversion of ferric enterobactin to monomer, dimer, and trimer products, just as the native enzyme ferric enterobactin esterase does. It’s hard to get proteins designed from scratch, called de novo proteins, to catalyze reactions …

and more »

2018-01-18 Michael Zand NEWS

Can stem cell exosome therapy reduce fatal heart disease in diabetes? – UAB News

UAB NewsCan stem cell exosome therapy reduce fatal heart disease in diabetes?UAB NewsAided by a new, four-year, $2.64 million grant from the National Institutes of Health, Prasanna Krishnamurthy, DVM, Ph.D., and Jianyi “Jay” Zhang, M.D., Ph.D., both in… Continue reading

2018-01-18 Michael Zand NEWS

Can stem cell exosome therapy reduce fatal heart disease in diabetes? – UAB News

2018-01-18 Michael Zand NEWS

UAB – News – $2.64M grant will probe use of stem cell exosome … – UAB News

UAB NewsUAB – News – $2.64M grant will probe use of stem cell exosome …UAB NewsPrasanna Krishnamurthy, DVM, Ph.D.Macrophage cells routinely remove dead or dying cells to maintain the body homeostasis. Such removal becomes crucial…and more &raquo… Continue reading

2018-01-18 Michael Zand NEWS

Juno And Other Gene Therapy Players Are Hot Despite Ongoing Pricing Debates – Forbes

ForbesJuno And Other Gene Therapy Players Are Hot Despite Ongoing Pricing DebatesForbesMore than 300 pharma and biotech companies are working on gene therapy products, and Juno ties for first place on that list when ranked by the size of its developmen… Continue reading

2018-01-18 Michael Zand NEWS

1
…
645
646
647
648
649
…
2,487

FierceBiotech

Gilead/Kite team up with Pfizer for CAR–T-mAb combination
FierceBiotech
Yescarta (axicabtagene ciloleucel), approved by the FDA last year in the first wave of new CAR–T cell therapies, will be teamed up with Pfizer’s experimental humanized 4-1BB agonist utomilumab in patients with refractory large B-cell lymphoma. The …
Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel …Business Wire (press release)

all 3 news articles »

Login

Cart

Tag Archives: The Stem Cell Blog

Designed enzyme rescues live bacteria | January 22, 2018 Issue … – The Biological SCENE

Stem Cell Transplant Results Better than Standard Therapy in Severe Scleroderma Patients, Phase 2 Trial Shows – Scleroderma News

Global Synthetic Biology Workstation Market 2018-2022 – Increasing … – Business Wire (press release)

Gilead/Kite team up with Pfizer for CAR-T-mAb combination – FierceBiotech

Can stem cell exosome therapy reduce fatal heart disease in diabetes? – UAB News

Can stem cell exosome therapy reduce fatal heart disease in diabetes? – UAB News

UAB – News – $2.64M grant will probe use of stem cell exosome … – UAB News

Juno And Other Gene Therapy Players Are Hot Despite Ongoing Pricing Debates – Forbes